Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Oncogene

• Publication date

  1995-05-04

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 7538656
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase C gamma or GTPase-activating protein, distinguishes ErbB-3 signaling from that of other ErbB/EGFR family members

  1994cited by this paper
• Phosphatidylinositol-3-OH kinase direct target of Ras

  1994cited by this paper
• Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity.

  1994cited by this paper
• ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor

  1994cited by this paper
• A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling.

  1994cited by this paper
• Identification of c‐erbB‐3 binding sites for phosphatidylinositol 3′‐kinase and SHC using an EGF receptor/c‐erbB‐3 chimera.

  1994cited by this paper
• The erbB3 gene product is a receptor for heregulin.

  1994cited by this paper
• The high transforming potency of erbB-2 and ret is associated with phosphorylation of paxillin and a 23 kDa protein.

  1994cited by this paper
• Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin.

  1994cited by this paper
• Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system

  1993cited by this paper
• Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family.

  1993cited by this paper
• ARIA, a protein that stimulates acetylcholine receptor synthesis, is a member of the neu ligand family.

  1993cited by this paper
• Demonstration of ligand-dependent signaling by the erbB-3 tyrosine kinase and its constitutive activation in human breast tumor cells.

  1993cited by this paper
• Heterodimerization of c-erbB2 with different epidermal growth factor receptor mutants elicits stimulatory or inhibitory responses.

  1992cited by this paper
• Neu differentiation factor: a transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit.

  1992cited by this paper
• Identification of Heregulin, a Specific Activator of p185erbB2

  1992cited by this paper
• Expression of the ERBB3 gene product in breast cancer.

  1992cited by this paper
• Oncogenes and signal transduction.

  1991cited by this paper
• Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.

  1991cited by this paper
• EGF receptor and erbB-2 tyrosine kinase domains confer cell specificity for mitogenic signaling.

  1990cited by this paper
• Molecular cloning and expression of an additional epidermal growth factor receptor-related gene.

  1990cited by this paper
• Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation.

  1990cited by this paper
• Evidence for epidermal growth factor (EGF)-induced intermolecular autophosphorylation of the EGF receptors in living cells

  1990cited by this paper
• Signal transduction by receptors with tyrosine kinase activity.

  1990cited by this paper
• Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function.

  1990cited by this paper
• HER-2/neu oncogene protein and prognosis in breast cancer.

  1989cited by this paper
• Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts.

  1989cited by this paper
• A point mutation in the neu oncogene mimics ligand induction of receptor aggregation

  1989cited by this paper
• Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

  1989cited by this paper
• Analysis of mammalian fibroblast transformation by normal and mutated human EGF receptors.

  1989cited by this paper
• Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors.

  1989cited by this paper
• Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene

  1988cited by this paper
• Signal transduction by allosteric receptor oligomerization.

  1988cited by this paper
• EGF‐stimulated tyrosine phosphorylation of p185neu: a potential model for receptor interactions.

  1988cited by this paper
• Oncogenic activation of the neu‐encoded receptor protein by point mutation and deletion.

  1988cited by this paper
• Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading.

  1988cited by this paper
• Egf binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB‐2 protein in the mammary tumor cell line SK‐BR‐3.

  1988cited by this paper
• Ligand activation of overexpressed epidermal growth factor receptors transforms NIH 3T3 mouse fibroblasts.

  1988cited by this paper
• erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells.

  1987cited by this paper
• Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells.

  1987cited by this paper
• Amplification of the neu (c-erbB-2) oncogene in human mammmary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene

  1987cited by this paper
• Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene.

  1987cited by this paper
• Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells.

  1987cited by this paper
• Overexpression of the EGF receptor‐related proto‐oncogene erbB‐2 in human mammary tumor cell lines by different molecular mechanisms.

  1987cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper
• Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo.

  1986cited by this paper
• Isolation and characterization of full-length cDNA clones for human alpha-, beta-, and gamma-actin mRNAs: skeletal but not cytoplasmic actins have an amino-terminal cysteine that is subsequently removed

  1983cited by this paper
• The nucleotide sequence of the rat cytoplasmic beta-actin gene.

  1983cited by this paper

• Emerging importance of HER3 in tumorigenesis and cancer therapy

  2025cites this paper
• HER2/neu as a Signaling and Therapeutic Marker in Uterine Serous Carcinoma

  2025cites this paper
• MiR-200c synergizes with trastuzumab-loaded gold nanoparticles to overcome resistance in ovarian cancer cells

  2025cites this paper
• Structural analysis of HER2-trastuzumab complex reveals receptor conformational adaptation

  2025cites this paper
• KRAS-Wild Pancreatic Cancer—More Targets than Treatment Possibilities?

  2025cites this paper
• The Evolving Paradigm of Antibody–Drug Conjugates Targeting the ErbB/HER Family of Receptor Tyrosine Kinases

  2024cites this paper
• Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study

  2024cites this paper
• Prevalence of HER3 Expression in Pancreatic Cancer Patients Treated With Systemic Chemotherapy

  2024cites this paper
• Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies

  2024cites this paper
• A kinome drug screen identifies multi-TKI synergies and ERBB2 signaling as a therapeutic vulnerability in MYC/TYR subgroup ATRTs.

  2024cites this paper
• A therapeutic algorithm guiding subsequent therapy selection after CDK4/6 inhibitors' failure: a review of current and investigational treatment for HR+/Her2- breast cancer.

  2024cites this paper
• A review of recombinant HER3 affibodies with an effective diagnostic view of cancer cells

  2024cites this paper
• Busting the Breast Cancer with AstraZeneca's Gefitinib

  2023cites this paper
• HER3: Toward the Prognostic Significance, Therapeutic Potential, Current Challenges, and Future Therapeutics in Different Types of Cancer

  2023cites this paper
• Targeting HER3 for cancer treatment: a new horizon for an old target

  2023cites this paper
• Antitumor activities against breast cancers by an afucosylated anti‐HER2 monoclonal antibody H2Mab‐77‐mG2a ‐f

  2023cites this paper
• Structure and dynamics of the EGFR/HER2 heterodimer

  2023cites this paper
• β-Escin overcomes trastuzumab resistance in HER2-positive breast cancer by targeting cancer stem-like features

  2022cites this paper
• Beyond HER2: Targeting the ErbB receptor family in breast cancer.

  2022cites this paper
• Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer

  2022cites this paper
• Targeting the complexity of ERBB2 biology in gastroesophageal carcinoma.

  2022cites this paper
• Targeting the HER3 pseudokinase domain with small molecule inhibitors.

  2022cites this paper
• An ErbB Lineage Co-Regulon Harbors Potentially Co-Druggable Targets for Multimodal Precision Therapy in Head and Neck Squamous Cell Carcinoma

  2022cites this paper
• Src family kinases, adaptor proteins and the actin cytoskeleton in epithelial-to-mesenchymal transition

  2021cites this paper
• HER2 activation and endocrine treatment resistance in HER2-negative breast cancer.

  2021cites this paper
• The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers

  2021cites this paper
• Molecular Mechanisms Associated with Brain Metastases in HER2-Positive and Triple Negative Breast Cancers

  2021cites this paper
• Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer

  2021cites this paper
• Inhibition of HER Receptors Reveals Distinct Mechanisms of Compensatory Upregulation of Other HER Family Members: Basis for Acquired Resistance and for Combination Therapy

  2021cites this paper
• EGFR TKIs Combinding the inhibition of RAS-ERK signaling in NSCLC Treatment

  2021cites this paper
• Interactions between ligand-bound EGFR and VEGFR2.

  2021cites this paper
• BCTT_A_288344 539..557

  2021cites this paper
• Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer

  2021cites this paper
• HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with RAS Wild Type Metastatic Colorectal Cancer

  2021cites this paper
• ANALYSIS OF THE EFFICACY AND CYTOTOXICITY OF A SYNTHESIZED ANTI-HER2 ANTIBODY-DRUG CONJUGATE

  2020cites this paper
• 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models

  2020cites this paper
• Potential tripeptides against the tyrosine kinase domain of human epidermal growth factor receptor (HER) 2 through computational and kinase assay approaches.

  2020cites this paper
• Neuregulin, an Effector on Mitochondria Metabolism That Preserves Insulin Sensitivity

  2020cites this paper
• A new anti-HER2 antibody that enhances the anti-tumor efficacy of trastuzumab and pertuzumab with a distinct mechanism of action.

  2020cites this paper
• Biallelic ERBB3 loss-of-function variants are associated with a novel multisystem syndrome without congenital contracture

  2019cites this paper
• Wrong place at the wrong time: how retrograde trafficking drives cancer metastasis through receptor mislocalization

  2019cites this paper
• Development of Effective Therapeutics Targeting HER3 for Cancer Treatment

  2019cites this paper
• HER3-targeted protein chimera forms endosomolytic capsomeres and self-assembles into stealth nucleocapsids for systemic tumor homing of RNA interference in vivo

  2019cites this paper
• The role of autophagy in HER2-targeted therapy.

  2019cites this paper
• Systems Biology in Biomarker Development for Cancer Signaling Therapy

  2019cites this paper
• Tetraspanin CD151 impairs heterodimerization of ErbB2/ErbB3 in breast cancer cells

  2019cites this paper
• Inhibition of DUSP6 sensitizes ovarian cancer cells to chemotherapeutic agents via regulation of ERK signaling response genes

  2019cites this paper
• The Role of the Ste20-like Kinase in Embryonic Development and Neu-induced Mammary Tumorigenesis

  2018cites this paper
• Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer.

  2018cites this paper
• The RTK Interactome: Overview and Perspective on RTK Heterointeractions.

  2018cites this paper
• Role Of d16HER2 Splice Variant In Breast Cancer Stem Cells

  2018cites this paper
• Functional genomic characterization of a synthetic anti-HER3 antibody reveals a role for ubiquitination by RNF41 in the anti-proliferative response

  2018cites this paper
• Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: History and status

  2018cites this paper
• Understanding the biology of HER3 receptor as a therapeutic target in human cancer

  2018cites this paper
• Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers

  2018cites this paper
• Metastatic squamous cell carcinoma of the skin with clinical response to lapatinib

  2018cites this paper
• A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer

  2017cites this paper
• The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation

  2017cites this paper
• Early clinical development of epidermal growth factor receptor targeted therapy in breast cancer

  2017cites this paper
• Molecular dynamics simulations of asymmetric heterodimers of HER1/HER2 complexes

  2017cites this paper
• HER2 somatic mutations are associated with poor survival in HER2‐negative breast cancers

  2017cites this paper
• ERBB2 Is Essential for the Growth of Chemically Induced Skin Tumors in Mice.

  2017cites this paper
• ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1)

  2017cites this paper
• Biophysical studies of the intracellular domains of the EGFR family of Receptor Tyrosine Kinases

  2017cites this paper
• 6.01 – Peptide-Based Cancer Vaccines and Therapeutics for Solid Tumors Overexpressing HER-1, HER-2, HER-3, VEGF and IGF-1R

  2017cites this paper
• Association of EGFR Gene Common Mutation with Uterine Fibroids in Iranian Affected Women

  2017cites this paper
• HER2-positive breast cancer cells expressing elevated FAM83A are sensitive to FAM83A loss

  2017cites this paper
• In Vitro and In Vivo Anti-tumoral Effects of the Flavonoid Apigenin in Malignant Mesothelioma

  2017cites this paper
• Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms

  2017cites this paper
• Fundamental Pathways in Breast Cancer 1: Signaling from the Membrane

  2017cites this paper
• State of the art in anti-cancer mAbs

  2017cites this paper
• SYSTEMAND METHOD TO INHIBIT HEREGULIN ACTIVATED PROCESSES AND OTHER METHODS USING SOLUBLE ERBB3 AND METHOD TO PRODUCE SOLUBLE ERBB3

  2017cites this paper
• Resistance to receptor-blocking therapies primes tumors as targets for HER3-homing nanobiologics

  2017cites this paper
• GLI pathogenesis-related 1 functions as a tumor-suppressor in lung cancer

  2016cites this paper
• Bimolecular complementation affinity purification (BiCAP) reveals dimer-specific protein interactions for ERBB2 dimers

  2016cites this paper
• ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomas

  2016cites this paper
• A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer

  2016influential citation
• Bispecific Radioimmunoconjugates for Molecular Imaging and Radioimmunotherapy of HER2 Overexpressing Breast Cancer

  2016cites this paper
• Protein arginine methyltransferase 5 regulates multiple signaling pathways to promote lung cancer cell proliferation

  2016cites this paper
• An anti-ErbB2 fully human antibody circumvents trastuzumab resistance

  2016cites this paper
• Targeting Tumors with Small Molecule Peptides.

  2016cites this paper
• Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China

  2016cites this paper
• Development of microfluidic device for high content analysis of circulating tumor cells

  2016cites this paper
• The Under-Appreciated Promiscuity of the Epidermal Growth Factor Receptor Family

  2016cites this paper
• PTPRO represses ERBB2-driven breast oncogenesis by dephosphorylation and endosomal internalization of ERBB2

  2016cites this paper
• Integrated analysis reveals that STAT3 is central to the crosstalk between HER/ErbB receptor signaling pathways in human mammary epithelial cells.

  2015cites this paper
• HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer

  2015cites this paper
• The Role of Sphingosine Kinase 1 in HER2/Neu-Induced Breast Tumorigenesis

  2015cites this paper
• A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy

  2015cites this paper
• Focal Adhesion Kinase (FAK) as a novel therapeutic target in HER2+ breast cancer

  2015cites this paper
• Regulation von Rezeptor-Tyrosinkinasen durch Opioide

  2015influential citation
• PI3K mutations in breast cancer: prognostic and therapeutic implications

  2015cites this paper
• Heregulin, a new regulator of telomere length in human cells

  2015cites this paper
• Nuclear Functions of Receptor Tyrosine Kinases

  2015cites this paper
• The EGFR/ERBB Receptor Family

  2015cites this paper
• MiR-4728-3p could act as a marker of HER2 status

  2015cites this paper
• A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK.

  2015cites this paper
• Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies.

  2015cites this paper
• Loss Is Associated with Worse Outcome in HER 2-Ampli fi ed Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance

  2015cites this paper
• Personalisation of therapy in advanced colorectal cancer

  2015cites this paper